<DOC>
	<DOCNO>NCT00425061</DOCNO>
	<brief_summary>Primary purpose assess IMA-638 safe improves asthma subject persistent asthma .</brief_summary>
	<brief_title>Study Evaluating Effect IMA-638 Subjects With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Generally healthy men woman persistent asthma , 18 70 year age , body weight 50 kg 115 kg . History treatment medium high dose inhale corticosteroid ( ICS ) , without longacting betaagonists ( LABA ) , least 2 month prior screen visit must remain constant study . FEV1 ≥ 55 % ≤ 80 % predict demonstrated improvement FEV1 ( L ) inhale albuterol ( salbutamol ) ( reversibility ) ≥ 12 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>